Cargando…
A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288733/ http://dx.doi.org/10.1186/2051-1426-2-S3-P73 |
_version_ | 1782352016078536704 |
---|---|
author | Goswami, Trishna Canelos, Paola Parikh, Radhika |
author_facet | Goswami, Trishna Canelos, Paola Parikh, Radhika |
author_sort | Goswami, Trishna |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-4288733 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42887332015-01-15 A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas Goswami, Trishna Canelos, Paola Parikh, Radhika J Immunother Cancer Poster Presentation BioMed Central 2014-11-06 /pmc/articles/PMC4288733/ http://dx.doi.org/10.1186/2051-1426-2-S3-P73 Text en Copyright © 2014 Goswami et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Poster Presentation Goswami, Trishna Canelos, Paola Parikh, Radhika A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas |
title | A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas |
title_full | A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas |
title_fullStr | A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas |
title_full_unstemmed | A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas |
title_short | A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas |
title_sort | phase ib/ii open-label study to evaluate the safety and efficacy of medi-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive b cell lymphomas |
topic | Poster Presentation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288733/ http://dx.doi.org/10.1186/2051-1426-2-S3-P73 |
work_keys_str_mv | AT goswamitrishna aphaseibiiopenlabelstudytoevaluatethesafetyandefficacyofmedi551incombinationwithimmunomodulatingtherapyinpatientswithrelapsedorrefractoryaggressivebcelllymphomas AT canelospaola aphaseibiiopenlabelstudytoevaluatethesafetyandefficacyofmedi551incombinationwithimmunomodulatingtherapyinpatientswithrelapsedorrefractoryaggressivebcelllymphomas AT parikhradhika aphaseibiiopenlabelstudytoevaluatethesafetyandefficacyofmedi551incombinationwithimmunomodulatingtherapyinpatientswithrelapsedorrefractoryaggressivebcelllymphomas AT goswamitrishna phaseibiiopenlabelstudytoevaluatethesafetyandefficacyofmedi551incombinationwithimmunomodulatingtherapyinpatientswithrelapsedorrefractoryaggressivebcelllymphomas AT canelospaola phaseibiiopenlabelstudytoevaluatethesafetyandefficacyofmedi551incombinationwithimmunomodulatingtherapyinpatientswithrelapsedorrefractoryaggressivebcelllymphomas AT parikhradhika phaseibiiopenlabelstudytoevaluatethesafetyandefficacyofmedi551incombinationwithimmunomodulatingtherapyinpatientswithrelapsedorrefractoryaggressivebcelllymphomas |